The Baker Brothers have lost 44.6% of their confidence.
That glass half-empty perspective means they've retained 55.4% of their optimism. But the fact remains that Baker Bros Advisors LLC, famous for their biotechnology sector holdings have liquidated 785k Synergy shares, retaining 973k. They're currently $4,446,000 underwater.
The constipation market place is crowded and getting more competitive each and every day. It includes some of the biggest names in biotech including Salix (NASDAQ:SLXP); Cubist, recently acquired by Merck (NYSE:MRK); AstraZeneca (NYSE:AZN) and Shire (NASDAQ:SHPG), not to mention a handful of hungry upstarts. However, it's not the presence of competition but the steady drum beat of news surrounding their products - all positive of late, that has caused Synergy to fall further behind in the lens of investor perception. Each time a news story breaks, Synergy's entrance into the market fray appears further and further away.